Table of Contents
<< Previous Issue | May 2013 (Vol: 2013, Issue: 5) | Next Issue >> |
- Section: Joint Venture
-
Vectura Forays into China by Forming JV with Tianjin KingYork and Zendex Bio Strategy
- Section: Licensing
-
Merck & Co. Out-Licenses Second CNS Programme to Cerecor
- Section: Mergers & Acquisitions
-
Bayer Boosts Contraceptive Business with US$1.1 B Conceptus Purchase
-
Takeda Joins the Dengue Vaccine Race with Inviragen Purchase
-
Actavis Agrees US$8.5 B Buyout of Warner Chilcott to Expand Speciality Drug Portfolio
- Section: Research & Development
-
AstraZeneca Continues Early-Stage Deal-Making Spree with Alchemia Deal
-
Forma Therapeutics Partners with Celgene in its Largest Deal to Date
-
Merck & Co. Collaborates with Pfizer and Abide Therapeutics with Aim of Bolstering Diabetes Portfolio
-
Concert Pharmaceuticals Snags Celgene as a Partner for its DCE Platform®
-
Shire Partners with Nimbus Discovery to Develop Oral Therapies for Lysosomal Storage Disorders